Robert Russell, MD
Internal Medicine · Lafayette, INNPI 1407052376
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,575 of the $18,747 with a category attached, or 61.7%. 22 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 32.4% of the total. Reporting peaked in 2023 at $5,710 and has fallen 82.0% since, to $1,025 in 2025. Among internal medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $132.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$6K
- Eli Lilly$4K
- Lilly USA, LLC$4K
- Sun Pharmaceutical Industries Inc.$1K
- AstraZeneca$552
- Acadia Pharmaceuticals Inc$389
- plus $1K from 16 others
What the payments were for
- Consulting fees$11,57562%
- Travel & lodging$1,86210%
- Food & beverage$5,31028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 30 | $6,072 |
| Eli Lilly | 2 | $4,425 |
| Lilly USA, LLC | 19 | $4,385 |
| Sun Pharmaceutical Industries Inc. | 17 | $1,500 |
| AstraZeneca | 15 | $552 |
| Acadia Pharmaceuticals Inc | 4 | $389 |
| Medline Industries LP | 3 | $346 |
| Pfizer | 16 | $271 |
| Otsuka America Pharmaceutical, Inc. | 2 | $140 |
| Johnson & Johnson | 7 | $139 |
| Sunovion Pharmaceuticals Inc. | 3 | $131 |
| Astellas Pharma US Inc | 5 | $95 |
| Abbott | 3 | $63 |
| Avanir Pharmaceuticals, Inc. | 4 | $61 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Novo Nordisk | 2 | $28 |
| Mylan Specialty L.p. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Boehringer Ingelheim | 1 | $13 |
| Novartis | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$4,425
- EZALLOR SPRINKLE$470
- KAPSPARGO$470
- NUPLAZID$369
- DRIZALMA SPRINKLE$347
- LOKELMA$246
- INGREZZA$230
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- APTIOM$110
How this compares
$18,747 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $52,977 |
| JardianceEmpagliflozin | 47 | $13,811 |
| JanuviaSitagliptin Phosphate | 38 | $10,690 |
| MyrbetriqMirabegron | 34 | $8,646 |
| XareltoRivaroxaban | 16 | $4,726 |
| Potassium Chloride | 116 | $3,618 |
| Midodrine Hcl | 18 | $3,584 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $3,456 |
| Divalproex Sodium | 51 | $3,131 |
| Gabapentin | 157 | $2,988 |
| Aripiprazole | 18 | $2,617 |
| Duloxetine Hcl | 57 | $2,588 |
| Atorvastatin Calcium | 182 | $2,206 |
| Lidocaine | 14 | $2,123 |
| Sevelamer Carbonate | 11 | $2,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $271 | $52,977172 claims |
| Boehringer IngelheimJardiance | $13 | $13,81147 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $8,64634 claims |
| Johnson & JohnsonXarelto | $139 | $4,72616 claims |
| Sanofi-aventis U.S. LLCLantus | $26 | $1,64122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Lafayette
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
- David IloFort Wayne$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.